

INTRODUCTION

- Representative EGFR-TKIs, such as gefitinib, afatinib, and osimertinib, have become the first-line standard treatment for patients with classical EGFR mutations (exon 19 deletions and exon 21 L858R) non-small cell lung cancer, with Progression-Free Survival (PFS) ranging from 10 to 20 months. However, this duration is still insufficient to meet the clinical needs.
- Therefore, more effective and safer combination therapy strategies are urgently required for exploration.

METHODS

- Between December 2018 and July 2023, we retrospectively collected data from 40 patients in our hospital who received first-line EGFR-TKI treatment in combination with Radioactive seed implantation (RSI).
- At the 2025 ESMO ASIA Congress, we reported baseline information and PFS data (Abstracts 1073eP).
- Here, we update the PFS and OS data from this study.
- The data cutoff is March 19, 2026.

DISCUSSION AND CONCLUSION

Actionable Take Away Message

- EGFR-TKI therapy combined with RSI confers a significant PFS benefit and merits further prospective investigation.

Future Direction for Research

- This study employed a single-arm design with a small sample size, necessitating larger randomized controlled trials to confirm these findings.

REFERENCES

- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*. 2009;361(10):947-957.
- Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*. 2012;13(3):239-246.
- Sequist LV, Yang JCH, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol*. 2013;31(27):3327-3334.
- Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N Engl J Med*. 2018;378(2):113-125.
- Chen E, Wang J, Zhang H, et al. Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer. *J Contemp Brachytherapy*. 2021;13(3):347-357.
- Ji L, Huo W, Liu Z, et al. Clinical outcome of CT-guided stereotactic ablative brachytherapy for unresectable early non-small cell lung cancer: a retrospective, multicenter study. *Front Oncol*. 2021;11:743140.
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45(2):228-247.
- Li X, et al. Baseline information and PFS data of radioactive seed implantation combined with EGFR-TKI in first-line treatment of classical EGFR mutation NSCLC. *ESMO Asia 2025*. Abstract 1073eP.

RESULTS

- The median follow-up for Overall survival (OS) was 49.1 months, and the median follow-up for PFS was 42.5 months.
- The median PFS for the overall population was 34.1 (95% CI,25.0-NR) months with the maturity of 55% (Fig. 1), and it's 39.9 (95% CI,28.4-NR) months for OS with the maturity of 42.5% (Fig. 2).
- The updated DOR is 21.6 (95% CI,14.5-39.7) months (Table 1).
- The safety profile remained consistent, with no additional safety signals observed.




Fig 1. PFS in All patients




Fig 2. OS in All patients




Fig 3. Patients receiving 1st EGFR-TKIs




Fig 4. Patients receiving 2nd EGFR-TKIs




Fig 5. Patients receiving 3rd EGFR-TKIs

Table 1. Tumor remission status

Outcome	Total (n = 40)
BOR,n(%)	
CR	0
PR	35
SD	5
PD	0
NE	0
ORR,(95% CI)	87.5 (73.2-95.8)
DCR, %(95% CI)	100 (91.2-100)
DOR,median(95% CI),months	21.6(14.5-39.7)